Drug Profile
Research programme: inflammation and immune disorder therapeutics - Asterand
Alternative Names: R99 programme - AsterandLatest Information Update: 13 Feb 2007
Price :
$50
*
At a glance
- Originator Asterand plc
- Class Small molecules
- Mechanism of Action Dinoprostone agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders; Inflammation
Most Recent Events
- 13 Feb 2007 Discontinued - Preclinical for Immunological disorders in United Kingdom (unspecified route)
- 13 Feb 2007 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
- 30 Jan 2006 Pharmagene has merged with Asterand to form Asterand plc